CYP-P22 biocatalytic nanoparticles with cytochrome P450 activity for prodrug activation
AssigneeUniversidad Nacional Autonoma De Mexico
InventorsRafael Vazquez Duhalt, Lorena Paulina Sanchez Sanchez
Life of this patent
Estimating the term…
Abstract
Hybrid proteins with cytochrome P450 activity and which are encapsulated in a nanocapsid (nanoparticles charged with cytochrome P450 activity) are designed and synthesized, these hybrid proteins being immunologically inert and recognized by breast cancer cells.
Claims17
An immunologically inert and functionalized CYP-P22 biocatalytic nanoparticle that activates prodrugs in a target cell, comprising
- a) a polypeptide sequence of SEQ ID NO:4 which is a fusion of a scaffold protein SP and a CYPBM3 protein,
- b) a fragment of a P22 scaffold protein,
- c) a coat protein of P22 bacteriophage,
- d) a bifunctional dendritic polyethylene glycol, and
- e) a cyclic polypeptide of SEQ ID NO:
- 5.
An immunologically inert and functionalized CYP-P22 biocatalytic nanoparticle that activates prodrugs in a target cell, for the manufacture of a medicine useful for contributing in the treatment of cancer of a mammalian or human patient, comprising:
- a) a polypeptide sequence of SEQ ID NO:4 which is a fusion of a scaffold protein SP and a CYPBM3 protein,
- b) a fragment of a P22 scaffold protein,
- c) a coat protein of P22 bacteriophage,
- d) a bifunctional dendritic polyethylene glycol, and
- e) a cyclic polypeptide of SEQ ID NO:
- 5.
Dependencies are inferred from the claim text.